收藏切换
Cost-utility analysis of dimethyl fumarate compared with teriflunomide for the treatment of relapsing multiple sclerosis in China
收藏切换
Mingjun RUI1, Xiwen DU1, Li XIE1, Haijun CAO1, Jian YIN2, *
World Clinical Drug | 2022, 43(11) : 1475 - 1485
Less
收藏切换
World Clinical Drug | 2022, 43(11): 1475-1485
• Article •
Cost-utility analysis of dimethyl fumarate compared with teriflunomide for the treatment of relapsing multiple sclerosis in China
Full
Mingjun RUI1, Xiwen DU1, Li XIE1, Haijun CAO1, Jian YIN2, *
Affiliations
  • 1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China
  • 2.Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China
Published: 2022-11-10 doi: 10.13683/j.wph.2022.11.015
Outline
收藏切换
Objective

This study aims to evaluate the cost-utility of dimethyl fumarate (DMF) compared with teriflunomide (TFM) for relapsing multiple sclerosis (RMS) in China.

Method

A Markov model was constructed based on a from healthcare system perspective in China over a 37-year horizon. Drug acquisition costs, monitoring costs, disease management costs, disease relapse costs and adverse events management costs were included. QALYs was used as the outcome. Utility of different model statuses and disutility caused by adverse events were also considered in the inputs. Costs and utility inputs were derived from published studies, public documents, and expert interviews. One-way sensitivity analysis (DSA) and probability sensitivity analysis (PSA) were conducted to evaluate the robustness of the results.

Results

Over a 37-year time horizon, DMF led to an incremental QALY gain of 0.16 (4.10 of DMF and vs 3.94 of TFM) and reduced the total cost of ¥128,923 yuan (¥513,105 of DMF and vs ¥642,028 of TFM) compared with TFM. Cost savings are mainly drug acquisition costs, monitoring costs, disease management costs, disease relapse costs and adverse events management costs. DSA results showed that the disability progression hazard ratio values of TFM and DMF were the main drivers. PSA results showed a 100% probability of DMF being cost-effective compared to TFM at a threshold of 1 GDP per capita.

Conclusion

DMF dominates the TFM for the treatment of RMS from healthcare system perspective in China.

dimethyl fumarate  /  teriflunomide  /  cost-utility  /  relapsing multiple sclerosis
芮明军, 杜夕雯, 谢丽, 曹海俊, 殷剑. 富马酸二甲酯治疗复发缓解型多发性硬化的成本效果分析. 世界临床药物, 2022 , 43 (11) : 1475 -1485 . DOI: 10.13683/j.wph.2022.11.015
Mingjun RUI, Xiwen DU, Li XIE, Haijun CAO, Jian YIN. Cost-utility analysis of dimethyl fumarate compared with teriflunomide for the treatment of relapsing multiple sclerosis in China[J]. World Clinical Drug, 2022 , 43 (11) : 1475 -1485 . DOI: 10.13683/j.wph.2022.11.015
Year 2022 volume 43 Issue 11
7
0
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.11.015
  • Receive Date:2022-08-11
  • Online Date:2026-11-18
  • Published:2022-11-10
Article Data
Affiliations
History
  • Received:2022-08-11
Affiliations
    1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China
    2.Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.11.015
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT